Sun Pharma Advanced Research Company Limited has informed the Exchange regarding a press release dated November 20, 2025, titled "SPARC announces Complete Response Letter Resubmission for PDP-716 NDA by Ocuvex".
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.8 pts more than Nifty Microcap 250 and 5.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sun Pharma Advanced Research Company (SPARC) has announced a resubmission of the New Drug Application (NDA) for PDP-716, which is being developed through Ocuvex. A Complete Response Letter (CRL) is issued by the US FDA when additional information or clarification is needed before granting approval. The resubmission indicates SPARC has addressed the earlier concerns raised by the FDA and is reapplying for marketing approval of the drug. Ocuvex is the entity responsible for this product filing. The development signals continued progress in the US regulatory pathway for PDP-716.
This is a procedural step forward in the drug approval process but does not constitute approval. Investors should view it as progress with regulatory uncertainty still remaining, which could keep the stock sensitive to further FDA updates.